Systemic Lupus Erythematosus Market is expected to register growth at a CAGR of 6.0% over the forecast period

The global systemic lupus erythematosus market size is expected to register growth at a CAGR of 6.0% over the forecast period of 2021-2030.

 

Lupus, also known as systemic lupus erythematosus (SLE), is a chronic inflammatory disease that causes tissue inflammation throughout the body. Fatigue, fever, skin rashes, joint discomfort, malaise, and brief loss of cognitive ability are all prominent signs of the condition. Individuals may experience different signs and symptoms.




                                              

Download Request for Sample@ https://bit.ly/3Q48vIy

 

 

The kidneys, skin, joints, lungs, central nervous system, and blood-forming (hematopoietic) system are all affected by the condition, which affects connective tissues that provide strength and flexibility to bodily structures and many organs and systems. Although the primary aetiology of the condition is unknown, a complicated genetic and hormonal basis has been discovered in a few investigations. The severity of the disease varies from mild to severe, and it is more common in women, affecting people between the ages of 25 and 45. A form of lupus is said to affect at least 5.0 million people worldwide. The disease's therapies in development focus on a wide range of targets.

 

GROWTH DRIVERS:

With 30 trials completed, GlaxoSmithKline is presently the company with the most completed clinical trials for SLE, followed by AstraZeneca. Benlysta (2011), a medication developed by GlaxoSmithKline, is the only medicine approved for SLE in the last 50 years. The number of medicines in development for moderate to severe SLE without active renal disease and/or lupus nephritis is also rising, indicating that the market will continue to increase in the coming years.

 

Additionally, biologics for autoimmune disorders are gaining more physician approval and confidence as they significantly improve disease treatment. In addition, some of the main pipeline biologics that are now through phase III clinical trials are projected to hit the market in the next few years, fueling the market because these medications could provide more effective alternatives to the lupus nephritis patient population. Benlysta is also in high demand, particularly in developed nations. All of these variables are projected to have a substantial impact on market growth in the future years.

SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SEGMENTATION:

By Drug Classes:

·         NSAID

·         Corticosteroids

·         Antimalarials

·         Immunosuppressants

·         Biologics

 

By Route of Administration:

·         Oral

·         Intravenous

·         Subcutaneous

·         Topical

By Distribution Channel:

·         Retail Pharmacies

·         Hospitals

·         Online Pharmacies

 

By Region:

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

 

Immunosuppressants had the greatest share of the market in 2020, based on medication classifications. Due to factors such as the increased worldwide usage of methotrexate and other immunosuppressants due to their low cost and great accessibility, the sector is likely to continue to lead the market throughout the projection period. During the forecast period of 2021-2030, however, the biologics category is expected to increase at the fastest rate of 13.0 percent.

In terms of route of administration, the oral segment dominated the market in 2020, accounting for 54.0 percent of the market, followed by the intravenous sector. Over the forecast term, the tendency is expected to continue.

In 2020, the hospitals segment accounted for the biggest proportion of the market, followed by the retail pharmacies segment. During the projected period of 2021-2030, the categories are expected to maintain their market dominance.

 

KEY COMPANIES IN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET:

·         Pfizer

·         Novartis

·         Bayer

·         Amgen Inc.

·         Bristol-Myers Squibb Company

·         GlaxoSmithKline PLC

·         Immunomedics Inc.

·         Johnson & Johnson

·         MedImmune LLC

·         Merck Serono GmbH

·         Sanofi SA

·         Teva Pharmaceutical Industries Ltd.

·         UCB SA

·         F. Hoffmann-La Roche Ltd.

·         Hansa Medical Ab

·         Harbor Biosciences

·         Other Players

 

Read More Information: https://www.xresearch.biz/shop/systemic-lupus-erythematosus-market

 

                                

About Us:-

xResearch is a market research and consulting organization that uses unique data, expert analysis, and new technologies to create trusted intelligence on industries. Our research is focused on delivering an informed and impartial view on essential market data of industry, and it is primarily driven by an in-depth study covering the following parameters: Market Sizing and Forecasting, Market Segmentation, Competitive Analysis, Strategic Assessment and Business Modelling.

 

Contact:       
Company Name: 
xResearch
Contact Person:  James Lin
Email: 
sales@xresearch.biz
Phone: +1 718-618-4545

Comments

Popular posts from this blog

Microalgae Fertilizers Market is expected to increase at a compound annual growth rate (CAGR) of 12.1% from 2025 to 2035

Food Encapsulation Market is predicted to expand at a compounded annual growth rate (CAGR) of 6.8% during the forecast period

Food Thermometer Market is expected to increase at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2035